MicroRNA-143 acts as a tumor suppressor by targeting hexokinase 2 in human prostate cancer

American Journal of Cancer Research

Volumn 5, Issue 6, 2015, Pages 2056-2063

  Zhou, Peng ^a   Chen, Wei Guo ^a   Li, Xiao Wei ^a  

^a CHENGDU MILITARY GENERAL HOSPITAL   (China)

Author keywords

Growth; Hexokinase 2; Mir 143; Prostate cancer

Indexed keywords

HEXOKINASE; HEXOKINASE 2; MICRORNA 143; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; AEROBIC METABOLISM; ANAEROBIC GLYCOLYSIS; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION REGULATION; GLUCOSE METABOLISM; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MALE; NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN RNA BINDING;

EID: 85006189075     PISSN: None     EISSN: 21566976     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Thompson IM and Tangen CM. Prostate cancer screening comes of age. Lancet 2014; 384:2004-2006.
2. Thompson IM Jr, Cabang AB and Wargovich MJ. Future directions in the prevention of prostate cancer. Nat Rev Clin Oncol 2014; 11: 49-60.
3. DeMarzo AM, Nelson WG, Isaacs WB and Epstein JI. Pathological and molecular aspects of prostate cancer. Lancet 2003; 361: 955-964.
4. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116:281-297.
5. Ambros V. microRNAs: tiny regulators with great potential. Cell 2001; 107: 823-826.
6. Kong YW, Ferland-McCollough D, Jackson TJ and Bushell M. microRNAs in cancer management. Lancet Oncol 2012; 13: e249-258.
7. Ambs S, Prueitt RL, Yi M, Hudson RS, Howe TM, Petrocca F, Wallace TA, Liu CG, Volinia S, Calin GA, Yfantis HG, Stephens RM and Croce CM. Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res 2008; 68: 6162-6170.
8. Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL and Visakorpi T. MicroRNA expression profiling in prostate cancer. Cancer Res 2007; 67: 6130-6135.
9. Esau C, Kang X, Peralta E, Hanson E, Marcusson EG, Ravichandran LV, Sun Y, Koo S, Perera RJ, Jain R, Dean NM, Freier SM, Bennett CF, Lollo B and Griffey R. MicroRNA-143 regulates adipocyte differentiation. J Biol Chem 2004; 279: 52361-52365.
10. Lui WO, Pourmand N, Patterson BK and Fire A. Patterns of known and novel small RNAs in human cervical cancer. Cancer Res 2007; 67:6031-6043.
11. Chen X, Guo X, Zhang H, Xiang Y, Chen J, Yin Y, Cai X, Wang K, Wang G, Ba Y, Zhu L, Wang J, Yang R, Zhang Y, Ren Z, Zen K, Zhang J and Zhang CY. Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene 2009; 28:1385-1392.
12. Michael MZ, SM OC, van Holst Pellekaan NG, Young GP and James RJ. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res 2003; 1: 882-891.
13. Ugras S, Brill E, Jacobsen A, Hafner M, Socci ND, Decarolis PL, Khanin R, O'Connor R, Mihailovic A, Taylor BS, Sheridan R, Gimble JM, Viale A, Crago A, Antonescu CR, Sander C, Tuschl T and Singer S. Small RNA sequencing and functional characterization reveals MicroRNA-143 tumor suppressor activity in liposarcoma. Cancer Res 2011; 71: 5659-5669.
14. Akao Y, Nakagawa Y, Kitade Y, Kinoshita T and Naoe T. Downregulation of microRNAs-143 and -145 in B-cell malignancies. Cancer Sci 2007; 98: 1914-1920.
15. Ng EK, Tsang WP, Ng SS, Jin HC, Yu J, Li JJ, Rocken C, Ebert MP, Kwok TT and Sung JJ. MicroRNA-143 targets DNA methyltransferases 3A in colorectal cancer. Br J Cancer 2009; 101: 699-706.
16. Scherr M, Venturini L, Battmer K, Schaller-Schoenitz M, Schaefer D, Dallmann I, Ganser A and Eder M. Lentivirus-mediated antagomir expression for specific inhibition of miRNA function. Nucleic Acids Res 2007; 35: e149.
17. Gregersen LH, Jacobsen A, Frankel LB, Wen J, Krogh A and Lund AH. MicroRNA-143 downregulates Hexokinase 2 in colon cancer cells. BMC Cancer 2012; 12: 232.
18. Wilson JE. Isozymes of mammalian hexokinase:structure, subcellular localization and metabolic function. J Exp Biol 2003; 206:2049-2057.
19. Patra KC, Wang Q, Bhaskar PT, Miller L, Wang Z, Wheaton W, Chandel N, Laakso M, Muller WJ, Allen EL, Jha AK, Smolen GA, Clasquin MF, Robey RB and Hay N. Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. Cancer Cell 2013; 24: 213-228.
20. Avgeris M, Stravodimos K, Fragoulis EG and Scorilas A. The loss of the tumour-suppressor miR-145 results in the shorter disease-free survival of prostate cancer patients. Br J Cancer 2013; 108: 2573-2581.
21. Mathupala SP, Rempel A and Pedersen PL. Glucose catabolism in cancer cells: identification and characterization of a marked activation response of the type II hexokinase gene to hypoxic conditions. J Biol Chem 2001; 276:43407-43412.
22. Mathupala SP, Ko YH and Pedersen PL. Hexokinase-2 bound to mitochondria: cancer's stygian link to the "Warburg Effect" and a pivotal target for effective therapy. Semin Cancer Biol 2009; 19: 17-24.
23. Warburg O. On respiratory impairment in cancer cells. Science 1956; 124: 269-270.
24. Vander Heiden MG, Cantley LC and Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009; 324: 1029-1033.